PKO Investment Management Joint Stock Co Has $782,000 Stake in Edwards Lifesciences Corporation $EW

PKO Investment Management Joint Stock Co decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 41.2% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 10,000 shares of the medical research company’s stock after selling 7,000 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Edwards Lifesciences were worth $782,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter worth about $26,000. SouthState Corp bought a new stake in Edwards Lifesciences during the first quarter worth $27,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the second quarter worth $28,000. Tradewinds Capital Management LLC raised its position in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after acquiring an additional 205 shares in the last quarter. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences in the first quarter valued at $29,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 0.5%

Shares of NYSE EW opened at $76.15 on Friday. The company has a 50 day simple moving average of $77.37 and a 200 day simple moving average of $76.37. The firm has a market cap of $44.70 billion, a PE ratio of 10.96, a price-to-earnings-growth ratio of 3.67 and a beta of 1.05. Edwards Lifesciences Corporation has a 1 year low of $64.89 and a 1 year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the business earned $0.70 EPS. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 25th. Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Truist Financial upped their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research note on Friday, July 25th. Finally, BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 target price for the company in a report on Tuesday, July 29th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $87.06.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.